Basilea Pharmace Stock
StockStockPrice
Frequently asked questions
What is Basilea Pharmace's market capitalization?
What is the Earnings Per Share (EPS) for Basilea Pharmace?
What are the analyst ratings and target price for Basilea Pharmace's stock?
What is Basilea Pharmace's revenue over the trailing twelve months?
What is the EBITDA for Basilea Pharmace?
What is the free cash flow of Basilea Pharmace?
What is the 5-year beta of Basilea Pharmace's stock?
How many employees does Basilea Pharmace have, and what sector and industry does it belong to?
What is the free float of Basilea Pharmace's shares?
Financials
Market Cap
$624.33M5Y beta
1.07EPS (TTM)
-$0.319Free Float
12.11MRevenue (TTM)
$169.01MEBITDA (TTM)
-$7.53MFree Cashflow (TTM)
$10.36MPricing
Analyst Ratings
The price target is $75.70 and the stock is covered by 6 analysts.
Buy
5
Hold
1
Sell
0
Information
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
156
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker